Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Zealand Pharma A/S (ZLDPF)
:ZLDPF
Earnings Data
Report Date
May 08, 2025TBA Not Confirmed
Period Ending
2025 (Q1)Consensus EPS Forecast
-0.79Last Year’s EPS
-0.52Same Quarter Last Year
Moderate Buy
Based on 8 Analysts Ratings
---
Earnings Call Summary
Earnings Call Date:Feb 20, 2025
|% Change Since: -7.97%
|Next Earnings Date:May 08, 2025
Earnings Call Sentiment|Positive
The earnings call reflected a positive sentiment overall, with significant advancements in clinical trials and a strong financial position. However, challenges such as regulatory setbacks and partnership uncertainties were noted.Company Guidance
During the call, Zealand Pharma provided extensive guidance on their strategic plans and financial outlook for 2025. The company anticipates operating expenses to range between DKK2.0 billion and DKK2.5 billion, a significant increase from 2024, to support their mid-stage obesity pipeline and early-stage research efforts. They ended 2024 with a strong cash position of DKK9 billion, which is DKK7.4 billion higher than at the start of the year. Zealand Pharma plans to have three large phase 2b trials actively underway by the end of 2025, with a focus on their obesity assets, including Petrelintide and Dapiglutide. They are also preparing for phase three trials and enhancing their early-stage research, particularly for obesity and inflammation. Additionally, the company aims to formally commit to the Science Based Target initiative in 2025, as part of their sustainability strategy, which includes reducing greenhouse gas emissions and supporting the goals of the Paris Agreement.Transformational Year with Significant Clinical Advancements
2024 was a transformational year for Zealand Pharma with significant clinical advancements across the obesity pipeline, including the development of petrelintide and dapiglutide.
Rapid Enrollment in Petrelintide Phase 2b Trial
Enrollment for the phase 2b trial of petrelintide in people with overweight or obesity was significantly faster than initially anticipated, projected to complete by the end of Q1 2025.
Strong Cash Position
Zealand Pharma ended 2024 with a cash position of DKK9 billion, which is DKK7.4 billion higher than the start of the year.
Sustainability and Employee Engagement
The company launched its first dedicated sustainability strategy and maintained a high employee engagement score of 8.8 on a 10-point scale, with a decreased turnover rate of 7.3%.
---
ZLDPF Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
---
ZLDPF Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
| Feb 20, 2025 | $108.08 | $106.34 | -1.61% |
| Nov 07, 2024 | $125.31 | $119.04 | -5.00% |
| Aug 15, 2024 | $137.00 | $136.99 | >-0.01% |
| May 16, 2024 | $95.30 | $91.15 | -4.35% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
---
FAQ
When does Zealand Pharma A/S (ZLDPF) report earnings?
Zealand Pharma A/S (ZLDPF) is schdueled to report earning on May 08, 2025, TBA Not Confirmed.
What is Zealand Pharma A/S (ZLDPF) earnings time?
Zealand Pharma A/S (ZLDPF) earnings time is at May 08, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is ZLDPF EPS forecast?
ZLDPF EPS forecast for the fiscal quarter 2025 (Q1) is -0.79.
---